Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

400 India Drug Makers Said To Have Complied With Essential Drug Pricing

This article was originally published in PharmAsia News

Executive Summary

Four hundred drug makers in the India market reportedly have complied with a health ministry request to identify medicines considered essential to the nation's drug-pricing policy.

Four hundred drug makers in the India market reportedly have complied with a health ministry request to identify medicines considered essential to the nation's drug-pricing policy. India's National Pharmaceutical Pricing Authority said it had received responses to pricing requests from that many firms. The National Pharmaceutical Pricing Authority sought the information from drug makers as part of its effort to fix the prices of the drugs involved. (Click here for more)

"Government Receives Info On Essential Medicines From 400 Drug Makers" - Business Standard (India) (4/23/2013)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC084121

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel